Acute Myeloid Leukemia Therapeutics Market in G8 Countries worth $1.67 Billion by 2020

2011-12-19
Published : Dec-2011

The Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 – 2020) analyzes and studies the major market drivers, restraints, and opportunities in regions such as North America, Europe, and Japan.

Browse market data tables and in-depth TOC on Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 – 2020).
http://www.marketsandmarkets.com/Market-Reports/acute-myeloid-leukemia-therapeutics-market-526.html
Early buyers will receive 10% customization on reports.

Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body from infections caused by bacteria. Acute myeloid leukemia is divided into childhood acute myeloid leukemia and adult acute myeloid leukemia.

Acute myeloid leukemia has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

The acute myeloid leukemia therapeutics market in G8 countries was valued at $216 million in 2010 and is expected to grow at a CAGR of 28.40% from 2015 to 2020. The market was dominated by AVD regimen in 2010. AVD regimen accounted for the largest share; i.e. 54.08% of the acute myeloid leukemia therapeutics market in G8 Countries in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cytarabine drug and Quizartinib molecule, with sales amounting to $698 million, $285 million, and $234 million respectively.

According to WHO, acute myeloid leukemia is expected to be more prominent in the developed world due to genetic and environmental factor, and radiation exposure is the primary cause of all the types of acute myeloid leukemia. Global incidence of acute myeloid leukemia was 49,539 in 2008 with the developing countries. Total 62,226 new cases were recorded in 2010 with 95,211 and 129,837 as the predicted new cases for 2015 and 2020.

The U.S. dominates the leukemia drug market in North America with a 90.19% share; whereas Germany dominates the market of Europe with 35.04% share.

The major players in the market include Ambit Biosciences Corporation (U.S.), Celgene Corporation (U.S.), Cephalon Inc. (U.S.), Clavis Pharma ASA (Norway), Eisai Co. Ltd (Japan), Genzyme Corporation (U.S.), and Sunesis Pharmaceuticals Inc. (U.S.).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. They cover thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website www.marketsandmarkets.com

Contact:
Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
MarketsandMarkets Blog
http://www.marketsandmarkets.com
http://twitter.com/marketsmarkets

Filed in: Pharmaceutical, Therapeutics
More Reports
Title Price Buy Now

Fungemia Global Clinical Trials Review, H2, 2017

Fungemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Fungemia Global Clinical Trials Review, H2, 2017" provides an overview of Fungemia clinical trials scenario. This report provides top line data relating to the clinical trials on Fungemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500

Gastroparesis Global Clinical Trials Review, H2, 2017

Gastroparesis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Gastroparesis Global Clinical Trials Review, H2, 2017" provides an overview of Gastroparesis clinical trials scenario. This report provides top line data relating to the clinical trials on Gastroparesis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Filariasis Global Clinical Trials Review, H2, 2017

Filariasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Filariasis Global Clinical Trials Review, H2, 2017" provides an overview of Filariasis clinical trials scenario. This report provides top line data relating to the clinical trials on Filariasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Gall Stone Global Clinical Trials Review, H2, 2017

Gall Stone Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Gall Stone Global Clinical Trials Review, H2, 2017" provides an overview of Gall Stone clinical trials scenario. This report provides top line data relating to the clinical trials on Gall Stone. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Gaucher Disease Global Clinical Trials Review, H2, 2017

Gaucher Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Gaucher Disease Global Clinical Trials Review, H2, 2017" provides an overview of Gaucher Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Gaucher Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Fistula Global Clinical Trials Review, H2, 2017

Fistula Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Fistula Global Clinical Trials Review, H2, 2017" provides an overview of Fistula clinical trials scenario. This report provides top line data relating to the clinical trials on Fistula. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated......
$2500

Gallbladder Cancer Global Clinical Trials Review, H2, 2017

Gallbladder Cancer Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Gallbladder Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Gallbladder Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Gallbladder Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2017

Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2017" provides an overview of Pre-Diabetes/Impaired Glucose Tolerance clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Repo......
$2500

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2017

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2017" provides an overview of Focal Segmental Glomerulosclerosis (FSGS) clinical trials scenario. This report provides top line data relating to the clinical trials on Focal Segmental Glomerulosclerosis (FSGS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Tr......
$2500

Gastric Cancer Global Clinical Trials Review, H2, 2017

Gastric Cancer Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Gastric Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Gastric Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Gastric Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500